Identification of potential core genes in triple negative breast cancer using bioinformatics analysis

OncoTargets and Therapy
Man-Xiu LiJun Shao

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor clinical outcome and limited treatment options. Lacking molecular targets, chemotherapy is the main adjuvant treatment for TNBC patients. To explore potential therapeutic targets for TNBC, we analyzed three microarray datasets (GSE38959, GSE45827, and GSE65194) derived from the Gene Expression Omnibus (GEO) database. The GEO2R tool was used to screen out differentially expressed genes (DEGs) between TNBC and normal tissue. Gene Ontology function and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis were performed using the Database for Annotation, Visualization and Integrated Discovery to identify the pathways and functional annotation of DEGs. Protein-protein interaction of these DEGs was analyzed based on the Search Tool for the Retrieval of Interacting Genes database and visualized by Cytoscape software. In addition, we used the online Kaplan-Meier plotter survival analysis tool to evaluate the prognostic value of hub genes expression in breast cancer patients. A total of 278 upregulated DEGs and 173 downregulated DEGs were identified. Among them, ten hub genes with a high degree of connectivity were picked out. Overexpression of t...Continue Reading

Citations

Jul 26, 2019·BioMed Research International·Siying HeGuohua Yang
Oct 30, 2020·Cancer Management and Research·Shengnan WangJianjun Dong
Dec 11, 2020·BioMed Research International·Yuting XuFang Zheng
Nov 5, 2021·American Journal of Alzheimer's Disease and Other Dementias·Yajing ChengFei Wang

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE65194
GSE45827
GPL570

Methods Mentioned

BETA
chip

Software Mentioned

Cytoscape
Search Tool for
JetSet
GEO2R
Database for Annotation , Visualization and Integrated Discove...
STRING
DAVID
CytoHubba

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.